Compare Fiverr International Ltd (FVRR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Fiverr International Ltd trades at $8.8 (market cap $326.79M), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.4× Fiverr International Ltd's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| FVRR | RXRX | |
|---|---|---|
Market Cap | $326.79M | $1.78B |
Sector | Industrials | Health |
52-Week High | $26.67 | $6.79 |
52-Week Low | $8.75 | $2.84 |
Enterprise Value | $79.18M | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $9.42, up 2.39% on the day, but remains near its 52-week low amid bearish technical signals. The stock shows weak earnings momentum with Q2 2026 misses and lowered 2026 guidance due to AI disruption compressing demand for freelance services. Valuation ratios appear attractive with P/E of 11.63 and P/S of 0.83, while profitability metrics show modest improvement with net income margin at 7.18% for 2025.
The outlook is cautious with significant headwinds from AI adoption threatening Fiverr's core business model. Near-term risks include declining active buyers and revenue pressure, though current valuations may offer contrarian appeal if the company successfully adapts to AI challenges. Wall Street sentiment is neutral with 76% hold ratings and a $10.70 consensus price target suggesting limited upside.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
